Press release
The gene therapy market is estimated to be worth USD 11.6 billion in 2030, predicts Roots Analysis
Roots Analysis is pleased to announce the publication of its recent study, titled, “Gene Therapy Market (3rd Edition), 2019-2030”.
For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html
The report features an extensive study of the current market landscape of gene therapies, primarily focusing on gene augmentation-based therapies, oncolytic viral therapies and genome editing therapies. The study also features an elaborate discussion on the future potential of this evolving market. In addition to other elements, the study includes:
A detailed review of the overall landscape of gene therapies and genome editing therapies.
A discussion on the various types of viral and non-viral vectors.
A world map representation, depicting the most active geographies, and a bull’s eye analysis, highlighting the distribution of clinical-stage pipeline candidates by phase of development, type of vector and type of therapy.
A discussion on the regulatory landscape related to gene therapies across various geographies.
Detailed profiles of marketed and phase II/III and gene therapies.
An elaborate discussion on the various commercialization strategies that can be adopted by drug developers for use across different stages of therapy development.
A review of various emerging technologies and therapy development platforms that are being used to design and manufacture gene therapies.
An in-depth analysis of the various patents that have been filed / granted related to gene therapies and genome editing therapies, since 2016.
An analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2014-2019.
An analysis of the investments made at various stages of development in companies that are focused in this area, between 2014-2019.
An analysis of the big biopharma players engaged in this domain.
A case study on the prevalent and emerging trends related to vector manufacturing, with information on companies offering contract services for manufacturing vectors.
A discussion on the various operating models adopted by gene therapy developers for supply chain management.
An analysis of the various factors that are likely to influence the pricing of gene-based therapies.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Key therapeutic areas
Autoimmune disorders
Cardiovascular diseases
Genetic disorders
Hematological disorders
Metabolic disorders
Ophthalmic disorders
Oncological disorders
Others
Type of vector
Adeno associated virus
Adenovirus
Herpes simplex virus type 1
Lentivirus
Plasmid DNA
Retrovirus
Vaccinia Virus
Type of therapy
Ex vivo
In vivo
Type of gene modification
Gene augmentation
Immunotherapy
Oncolytic therapy
Others
Route of administration
Intraarticular
Intracerebellar
Intramuscular
Intradermal
Intravenous
Intravitreal
Intravesical
Subretinal
Others
Key geographical regions
North America
Europe
Asia-Pacific
Transcripts of interviews held with the following senior level representatives of stakeholder companies
Adam Rogers (CEO, Hemera Biosciences)
Al Hawkins (CEO, Milo Biotechnology)
Buel Dan Rodgers (Founder & CEO, AAVogen)
Cedric Szpirer (Executive & Scientific Director, Delphi Genetics)
Christopher Reinhard (CEO and Chairman, Cardium Therapeutics)
Ryo Kubota (Chairman, President and Chief Executive Officer, Acucela)
Jeffrey Hung (CCO, Vigene Biosciences)
Marco Schmeer (Project Manager) & Tatjana Buchholz (Marketing Manager, PlasmidFactory)
Michael Triplett (CEO, Myonexus Therapeutics, acquired by Sarepta Therapeutics)
Robert Jan Lamers (CEO, Arthrogen)
Tom Wilton (Chief Business Officer, LogicBio Therapeutics)
Key companies covered in the report
Advantagene
Advaxis
BioMarin
bluebird bio
FKD Therapies
Freeline Therapeutics
GenSight Biologics
Gradalis
Inovio Pharmaceuticals
Marsala Biotech
Orchard Therapeutics
Pfizer
Sarepta Therapeutics
Spark Therapeutics
Tocagen
Transgene
uniQure Biopharma
VBL Therapeutics
ViroMed
For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html
Other Recent Offerings
1. Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)
2. CAR-T Therapies Market (2nd Edition), 2019-2030
3. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com
Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The gene therapy market is estimated to be worth USD 11.6 billion in 2030, predicts Roots Analysis here
News-ID: 2263223 • Views: …
More Releases from Roots Analysis
Rise in demand of glp-1 drugs for metabolic disorders.
In recent years, owing to its broader clinical potential in the treatment of obesity and type 2 diabetes, along with their proven efficacy in reducing cardiovascular risks, GLP-1 drugs market has garnered significant traction within the medical science domain.
Concurrently, the rising demand and escalating prevalence of metabolic disorder including type 2 diabetes and obesity are fueling the need for treatments capable of effectively managing these conditions. This trend is expected…
Carbon footprint management market is Set to Soar to USD 55.9 Billion by 2035
Carbon footprint refers to the measurement of greenhouse gas emissions, expressed in carbon dioxide equivalent. It is released into the atmosphere either directly or indirectly through various activities, processes, or products. These emissions originate from diverse sources, including energy consumption, manufacturing processes, transportation networks, and waste management strategies.
The global carbon footprint management market, valued at USD 12.2 billion in 2024, is expected to reach USD 13.5 billion in 2025…
Gene switches have garnered significant attention from drug developers owing to …
The global gene switch market size is estimated to grow from USD 795 million in 2025 to USD 2,478 million by 2035, representing a CAGR of 12.03% during the forecast period till 2035.
Driven by numerous developmental breakthroughs and encouraging study results demonstrating the vast potential of adoptive cell therapies (ACT), including CAR-T cell therapies, TCR therapies, TILs and natural killer cell therapies, in the treatment of various complex disorders, this…
Antibody Discovery Market Set to Soar to $6.6 Billion by 2035
Antibodies, also known as immunoglobulins, are Y-shaped glycoproteins that are produced by the immune system in response to foreign molecules (antigens) that enter the body. The term antigen refers to any substance that is capable of inducing an immune response, encompassing a diverse range of entities, including viruses, fungi, bacteria, proteins on the surface of cells, and non-living substances, such as toxins, chemicals and foreign particles.
The global antibody discovery…
More Releases for Therapeutics
Adrenomyeloneuropathy Market: Epidemiology, Therapies, Companies, DelveInsight | …
Adrenomyeloneuropathy emerging therapies are expected to boost the Adrenomyeloneuropathy Market in the upcoming years.
DelveInsight has launched a new report on "Adrenomyeloneuropathy - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Adrenomyeloneuropathy, historical and forecasted epidemiology as well as the Adrenomyeloneuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover about the Adrenomyeloneuropathy market report @ https://www.delveinsight.com/report-store/adrenomyeloneuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Some of the…
Pompe Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Genzyme …
Pompe Disease emerging therapies, such as MYOZYME (alglucosidase alfa), LUMIZYME, AAV2/8-LSPhGAA, Avalglucosidase alfa, and others, are expected to boost the Pompe Disease Market in the upcoming years.
DelveInsight has launched a new report on "Pompe Disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Pompe Disease, historical and forecasted epidemiology as well as the Pompe Disease market trends in the United States, EU5 (Germany, Spain,…
Dark Genome Therapeutics Market Deep Research Report with Forecast to 2032 | myN …
The qualitative latest Research report (2025-2032) on the Dark Genome Therapeutics Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves.
Request a Sample Copy: https://www.coherentmarketresearch.com/samplepages/133611
Focused on growth…
Hodgkin's lymphoma Therapeutics Market Size Report 2032 | Affimed Therapeutics, …
DelveInsight's "Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Hodgkin's Lymphoma, historical and forecasted epidemiology as well as the Hodgkin's Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United kingdom and Japan.
Discover Key Insights into the Hodgkin's lymphoma Market with DelveInsight's In-Depth Report @ Hodgkin's lymphoma Market Size- https://www.delveinsight.com/sample-request/hodgkins-lymphoma-hl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Hodgkin's…
CRISPR Therapies Pipeline 2024 | Intellia Therapeutics, CRISPR therapeutics, Rep …
DelveInsight's, "CRISPR Therapies Pipeline Insight 2024" report provides comprehensive insights about 25+ CRISPR Therapies Companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CRISPR Therapies therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive CRISPR Therapies pipeline products in this space.
Key Takeaways from…
Digital Therapeutics Market, Digital Therapeutics Market Size, Digital Therapeut …
The global digital therapeutics market is expected to reach US$ 8,941.1 Mn by 2025 from US$ 1,993.2 Mn in 2017. The market is estimated to grow with a CAGR of 20.8% during the forecast period from 2018 to 2025.
North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast period, whereas the market is expected to witness growth at a significant…
